PMID- 36597550
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 1177-889X (Print)
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 16
DP  - 2022
TI  - Patients' Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and 
      Glucagon-Like Peptide-1 Receptor Agonists.
PG  - 3415-3428
LID - 10.2147/PPA.S391719 [doi]
AB  - PURPOSE: To determine patients' preferences for sodium-glucose cotransporter 2 
      inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs). 
      PATIENTS AND METHODS: A cross-sectional, web-based discrete choice experiment was 
      conducted among US adults with type 2 diabetes mellitus (T2DM) in May 2021. Six 
      attributes-the route and frequency of administration, the chance of reaching 
      target HbA1c in six months, the percentage reduction in the risk of major adverse 
      cardiovascular events (MACE), the chance of gastrointestinal side effects, the 
      chance of genital infection, and out-of-pocket cost per month-were identified 
      from literature review and consultation with patients and clinicians. A Bayesian 
      efficient design was used to generate choice sets. Each choice set contained two 
      hypothetical SGLT-2i and GLP-1 RA alternatives described by the attributes and an 
      opt-out alternative. A total of 176 patients were asked to select the most 
      preferred option from each choice set. Mixed logit (ML) and latent class (LC) 
      models were developed. The conditional relative importance of each attribute was 
      determined. RESULTS: The ML model showed the out-of-pocket cost had the highest 
      conditional relative importance, followed by the chance of reaching the target 
      HbA1c. The best LC model revealed two patient classes. All attributes were 
      significantly important to the patients in both classes, except the chance of 
      genital infection in class 2. Compared to the patients in class 2, the patients 
      in class 1 were older (approximately 65 vs 56 years) and had a higher number of 
      comorbidities (approximately three vs two). CONCLUSION: T2DM patients placed 
      different preference weights or importance across SGLT-2i and GLP-1 RA 
      attributes. Preference heterogeneity was found among patients with different ages 
      and numbers of comorbidities.
CI  - (c) 2022 Banjara et al.
FAU - Banjara, Bidur
AU  - Banjara B
AUID- ORCID: 0000-0001-5448-2234
AD  - Department of Health Outcomes Research and Policy, Auburn University, Harrison 
      College of Pharmacy, Auburn, AL, USA.
AD  - Cytel Inc, Waltham, MA, USA.
FAU - Poudel, Nabin
AU  - Poudel N
AD  - Department of Health Outcomes Research and Policy, Auburn University, Harrison 
      College of Pharmacy, Auburn, AL, USA.
FAU - Garza, Kimberly B
AU  - Garza KB
AUID- ORCID: 0000-0002-4684-372X
AD  - Department of Health Outcomes Research and Policy, Auburn University, Harrison 
      College of Pharmacy, Auburn, AL, USA.
FAU - Westrick, Salisa
AU  - Westrick S
AUID- ORCID: 0000-0002-3497-0406
AD  - Department of Health Outcomes Research and Policy, Auburn University, Harrison 
      College of Pharmacy, Auburn, AL, USA.
FAU - Whitley, Heather P
AU  - Whitley HP
AUID- ORCID: 0000-0001-5124-4484
AD  - Department of Pharmacy Practice, Auburn University, Harrison College of Pharmacy, 
      Auburn, AL, USA.
FAU - Redden, David
AU  - Redden D
AD  - Department of Biomedical Affairs and Research, Auburn University, Edward via 
      College of Osteopathic Medicine, Auburn, AL, USA.
FAU - Ngorsuraches, Surachat
AU  - Ngorsuraches S
AD  - Department of Health Outcomes Research and Policy, Auburn University, Harrison 
      College of Pharmacy, Auburn, AL, USA.
LA  - eng
PT  - Journal Article
DEP - 20221228
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC9805720
OTO - NOTNLM
OT  - diabetes
OT  - discrete choice experiment
OT  - patient preference
OT  - second-line antihyperglycemic agents
COIS- The authors report no conflicts of interest in this work.
EDAT- 2023/01/05 06:00
MHDA- 2023/01/05 06:01
PMCR- 2022/12/28
CRDT- 2023/01/04 01:49
PHST- 2022/10/19 00:00 [received]
PHST- 2022/12/15 00:00 [accepted]
PHST- 2023/01/04 01:49 [entrez]
PHST- 2023/01/05 06:00 [pubmed]
PHST- 2023/01/05 06:01 [medline]
PHST- 2022/12/28 00:00 [pmc-release]
AID - 391719 [pii]
AID - 10.2147/PPA.S391719 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2022 Dec 28;16:3415-3428. doi: 10.2147/PPA.S391719. 
      eCollection 2022.